MiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest Update

Key Points

• MiNK Therapeutics, Inc. experienced an **85.9% drop** in short interest, with only **35,400 shares** sold short as of July 31st, compared to **250,900 shares** on July 15th.
• For the latest quarter, MiNK reported an **EPS of ($1.06)**, falling short of analysts' expectations of **($0.55)** by **$0.51**.
• Recent analyst ratings for MiNK include a **downgrade** by William Blair and an upgrade to **"strong-buy"** by B. Riley, with HC Wainwright setting a target price of **$35.00**.

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) was the recipient of a significant decrease in short interest in July. As of July 31st, there was short interest totaling 35,400 shares, adecreaseof85.9% from the July 15th total of 250,900 shares. Based on an average trading volume of 943,500 shares, the days-to-cover ratio is presently 0.0 days. Approximately3.6% of the shares of the company are sold short. Approximately3.6% of the shares of the company are sold short. Based on an average trading volume of 943,500 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Ratings Changes

Several brokerages have recently weighed in on INKT. B. Riley raised shares of MiNK Therapeutics to a "strong-buy" rating in a research report on Friday, July 18th. Zacks Research lowered shares of MiNK Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Monday. HC Wainwright raised shares of MiNK Therapeutics from a "neutral" rating to a "buy" rating and set a $35.00 price objective on the stock in a research report on Friday, August 15th. Finally, William Blair lowered shares of MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Friday, July 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, MiNK Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $37.50.

MiNK Therapeutics Stock Performance

NASDAQ:INKT traded down $0.23 during mid-day trading on Wednesday, reaching $14.47. 41,638 shares of the company's stock were exchanged, compared to its average volume of 174,466. MiNK Therapeutics has a one year low of $4.56 and a one year high of $76.00. The firm has a market capitalization of $65.40 million, a PE ratio of -5.02 and a beta of 0.33. The business's fifty day simple moving average is $14.35 and its two-hundred day simple moving average is $10.35.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.51). As a group, equities research analysts forecast that MiNK Therapeutics will post -2.75 EPS for the current year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.